

Date:- May 27, 2026

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051

BSE Script Code: 531599

NSE Symbol: FDC

Sub: Press Release on Q4 - FY 2026-27 and 12M - FY 2026-27 Results.

Dear Sir/Ma'am,

Please find attached herewith the Press Release issued in relation to the Audited Standalone and Consolidated Financial Results of the Company for the Quarter and Year ended March 31, 2026.

Kindly take the same on record.

Thanking you,

Yours truly

For FDC Limited

Varsharani Katre

Company Secretary & Legal Head

M No.: FCS-8948

FDC Limited announces Q4 FY26 results

Mumbai, May 27, 2026: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) has announced its financial results for the fourth quarter and year ended March 31, 2026.

Consolidated Financial Results for Q4 FY26 and FY26:

(Rs. in crores)

Particulars	Q4 FY26	Q4 FY25	Y-o-Y Grw %	FY26	FY25	Y-o-Y Grw %
Revenue from Operations	585	492	18.9%	2,171	2,108	3.0%
EBITDA	106	54	97.0%	346	325	6.6%
EBITDA Margin	18.2%	11.0%		15.9%	15.4%	
PBT (before exceptional items)	140	53	163.3%	395	357	10.7%
PBT (after exceptional items)	140	53	163.3%	375	357	4.9%
PAT	103	39	167.4%	281	267	5.5%
EPS (Rs.)	6.35	2.38	167.4%	17.29	16.39	5.5%

Q4 FY26 revenue from operations stood at Rs. 585 crores, registering a robust growth of 18.9% Y-o-Y. All the three business segments achieved healthy growth with Domestic Formulations business growing by 8.5%, Export Formulations business growing by 99.3% and API business growing by 38.6%. For FY26, revenue from operations stood at Rs. 2,171 crores with a growth of 3.0%.

The US business overcoming the earlier challenges delivered strong performance in Q4 FY26. Revenue from supplies stood at Rs. 71 crores reflecting a Y-o-Y growth of 165.1%, driven by improved execution and demand momentum. Overall US business revenue grew 46.9% Y-o-Y, with improved profit share from the US partners.

EBITDA for Q4 FY26 stood at Rs. 106 crores, with margins at 18.2% compared to 11.0% last year on the back of enhanced operational efficiencies. FY26 EBITDA margin improved from 15.4% to 15.9% Y-o-Y driven by higher gross margin.

Business Segment-wise Sales Performance

(Rs. in crores)

Particulars	Q4 FY26	Y-o-Y Grw %	FY26	Y-o-Y Grw%
Revenue from Operations	585	18.9%	2,171	3.0%
Domestic Formulations	452	8.5%	1,781	0.1%
Export Formulations (US)	39	283.1%	94	46.9%
Export Formulations (Non-US)	50	44.8%	166	13.3%
APIs	42	38.6%	121	8.5%

REGISTERED OFFICE

Domestic Formulations:

Domestic Formulations business bounced back in Q4 FY26 with a revenue of Rs. 452 crores registering a healthy growth of 8.5% Y-o-Y. For FY26, Domestic Formulations sales were Rs. 1,781 crores, displaying a muted growth of 0.1% compared to the corresponding period last year, due to subdued performance in top brands like Zifi, Electral and Enerzal. Domestic Formulations business contributed 78% to total consolidated sales during the quarter and 82% for FY26.

According to the secondary sales data by IQVIA (MAT March 31, 2026), the Company recorded a 1.7% growth.

Export Formulations:

Export Formulations sales stood at Rs. 89 crores in Q4 FY26, registering a growth of 99.3% Y-o-Y, contributing 15% to company's consolidated sales. For FY26, Export Formulations sales were Rs. 260 crores, reflecting a 23.5% growth compared to the same period last year. Export Formulations performance has improved consistently over the last 2–3 quarters, supported by improved supplies and better execution across US and focused markets.

During the quarter, the Company received U.S. FDA approval for Fluconazole Tablets USP 50mg, 100mg, 150mg and 200mg.

APIs:

API business registered sales of Rs. 42 crores in Q4 FY26, up by 38.6% Y-o-Y and accounting for 7% of total consolidated sales. During FY26, the API business grew by 8.5% registering sales of Rs. 121 crores.

ABOUT FDC LTD

FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmic. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Formulations. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.

REGISTERED OFFICE

Disclaimer

Except for the historical information contained herein, statements in this press release and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

REGISTERED OFFICE

FDC House, C-11 & 12, Dalia Industrial Estate, Oshiwara Village, Off New Link Road, Andheri (West), Mumbai - 400 053, Maharashtra, INDIA.
• Phones : +91-22-69107100 • E-mail : fdc@fdcindia.com • Website : www.fdcindia.com • CIN : L24239MH1940PLC003176